Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D.
You can check out Broadfin Capital’s latest holdings and filings here.
Please follow Broadfin Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings.
Follow Kevin Kotler's Broadfin Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Broadfin Capital | 0 | 2,236,025 | 0 | 2,236,025 | 11.67% | |
| Broadfin Healthcare Master Fund, Ltd | 0 | 2,236,025 | 0 | 2,236,025 | 11.67% | |
| Kevin Kotler | 0 | 2,236,025 | 0 | 2,236,025 | 11.67% |
Follow Kevin Kotler's Broadfin Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9 – SEC Filing
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE 13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)*
| Recro Pharma, Inc. |
| (Name of Issuer) |
| Common Stock, $0.01 par value per share |
| (Title of Class of Securities) |
| 75629F109 |
| (CUSIP Number) |
| Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 Telephone – (212) 808-2460 |
| (Name, Address and Telephone Number of Person Notices and Communications) |
| March 13, 2018 |
| (Date of Event Which Requires Filing of this Statement) |
| If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ _ ]. |
| Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent. |
______________
| * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). |
Follow Societal Cdmo Inc. (NASDAQ:SCTL)
Follow Societal Cdmo Inc. (NASDAQ:SCTL)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9
